Prognostic Factors in Gastrointestinal Stromal Tumours. by Aqib, K Shaick
PROGNOSTIC FACTORS IN 
GASTROINTESTINAL STROMAL TUMOURS 
 
Dissertation submitted to  
 
THE TAMILNADU  
Dr. MGR MEDICAL UNIVERSITY 
 
in partial fulfillment of the requirements for the award of degree of 
 
MCh (BRANCH VII) 
SURGICAL ONCOLOGY 
 
 
 
COLLEGE OF ONCOLOGICAL SCIENCES 
CANCER INSTITUTE (WIA) 
ADYAR  
CHENNAI – 600 020 
 
FEBRUARY 2008 
 ii
 
 
 
CERTIFICATE 
 
 
 
 
 I hereby certify that this is the bonafide work done by                 
Dr. AQIB K. SHAICK who is appearing for MCh Surgical Oncology 
(branch VII) final examination in February 2008, under my guidance in 
the College of Oncological Sciences, Cancer Institute (WIA), Adyar 
Chennai. 
 
 
 
 
 
Dr. HEMANTH RAJ MCh. PhD. 
Professor and Chairman 
Division of Surgical Oncology 
College of Oncological Sciences, 
Cancer Institute (WIA) 
Adyar, Chennai. 
 iii
 
 
 
ACKNOWLEDGMENT 
 
 
 
 
 I am very grateful to all the patients, whom I have served and from whom      
I have learnt. 
 
 I express my gratitude to Dr. S. Krishnamurthy, Advisor and                     
Dr. V. Shantha, Executive Chairman, College of Oncological Sciences, Cancer 
Institute (WIA), Adyar, for providing the facilities to carry out this study. 
 
 I am thankful to my teacher and guide in this project, Dr Hemant Raj, 
Professor and chairman Division of Surgical Oncology, College of Oncological 
Sciences, Cancer Institute (WIA), Adyar.  
 
 Iam also thankful to Dr A.S. Ramakrishnan associate professor Division of 
Surgical Oncology and Dr. Urmila Majhi, professor and Dr. Shirley. S associate 
professor Department of Pathology for their inputs. 
 
 I am also thankful for the support given by the administration of the Cancer 
Institute (WIA), headed by the Director and Scientific Director Dr. T Rajkumar.  
 
 I acknowledge the help rendered by the staff at the Tumor Registry and 
Epidemiology Division at the Cancer Institute (WIA). 
 iv
 
 
 
CONTENTS 
 
 
 
 
CHAPTER 
NO 
TITLE 
PAGE 
NO 
   
1. INTRODUCTION 1 
2. AIMS & OBJECTIVES 3 
3. MATERIALS & METHODS 4 
4. REVIEW OF LITERATURE 5 
5. RESULTS 40 
6. DISCUSSION 49 
7. CONCLUSION 54 
8. REFERENCES 55 
9. PROFORMA 60 
 
 
 
 
 
 
 
 
 
 v
 
 
 
INTRODUCTION 
 
 
 
 
 Gastrointestinal stromal tumours (GIST) are the most common 
mesenchymal tumours of the digestive tract. Most gastrointestinal soft 
tissue neoplasms, previously classified as leiomyomas, schwannomas, 
leiomyoblastomas or leiomyosarcomas, are today classified as GIST on 
the basis of molecular and immunohistological features. They originate 
from gastrointestinal pacemaker cells and are characterised by over-
expression of the tyrosine kinase receptor KIT. Overall 5-year survival 
after surgical resection of GIST is approximately 60%. However, these 
tumours span a wide clinical spectrum from benign to highly malignant. 
Prognostic factors have recently been identified for GIST and include 
tumour size, mitotic rate and other minor factors. At present, surgery is 
the standard treatment for primary resectable GIST. Benign GIST have 
an excellent prognosis after primary surgical treatment, with over 90% 5-
year survival. While recurrent or malignant GIST, which are resistant to 
radiotherapy and chemotherapy, had until recently an extremely poor 
prognosis even after surgical resection, with median survival of 12 
 vi
months. The development of a tyrosine kinase inhibitor has changed the 
management of unresectable malignant cases. This new tyrosine kinase 
inhibitor, imatinib mesylate, which inhibits the c-kit receptor, has proved 
highly effective against GIST and has improved survival in metastatic 
GIST.  
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AIMS & OBJECTIVES 
 
 
 
 
1. To find out the actual number of Gastrointestinal stromal tumours 
treated in our institute based on c-kit positivity. 
2. To identify the prognostic factors influencing recurrence and 
survival. 
3. To identify subgroup of patients, who might benefit from adjuvant 
therapy. 
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MATERIALS & METHODS 
 
 
 
 
 All the case records of patients who were diagnosed to have GIST 
(on the basis of c-kit positivity) were analysed individually. Case records 
of all the patients who were diagnosed to have intraabdominal sarcoma 
from the year 1999 to june 2007 were scrutinized. Paraffin blocks and 
slides of the above patients were retrieved from pathology dept. IHC 
study for c-kit were performed on the slides. All the c-kit positive cases 
were also included in the study. Of the 32 patients with GIST only 31 
were available for analysis. 
 
 Data was analysed using SPSS 10.0.1 structured package. 
 
 Survival was calculated by life table method.  
 
 Comparison of survival by different categories were done by log 
rank test. 
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REVIEW OF LITERATURE 
 
 
 
 
 Gastrointestinal stromal tumours (GISTs) are rare tumours of the 
gastrointestinal tract, mesentery, and omentum. However, malignant 
GIST is the most common sarcoma of the gastrointestinal tract and 
accounts for about 5% of all sarcomas.1 The estimated annual incidence 
is 10–20 cases per million, of which 20–30% are malignant.2 However, 
these estimates may need to be revised after the recent clearer definition 
of diagnostic criteria for GIST.3 Clinical, histopathological, 
ultrastructural, and molecular-biological findings, have made clear that 
GIST is completely separate from leiomyoma and leiomyosarcoma, 
which were previously thought to be the most common types of 
softtissue neoplasms in the gastrointestinal tract. Recent studies suggest 
that true gastrointestinal-tract leiomyomas and leiomyosarcomas are 
rare.2 
 
 The term GIST was first used by Mazur and Clark in 1983 to 
describe gastrointestinal non-epithelial neoplasms that lacked the 
 x
immunohistochemical features of Schwann cells and did not have the 
ultrastructural characteristics of smooth-muscle cells.4 The discovery of 
gain-of-function mutations in the KIT proto-oncogene in GISTs by 
Hirota and colleagues in 1998 was of crucial importance in terms of the 
genesis and classification of these tumours.5 This finding led to the 
development of rational, molecularly targeted therapy of GISTs with the 
KIT-receptor tyrosine-kinase inhibitor, imatinib mesylate (formerly 
known as STI571). 
 
 The KIT protein is the transmembrane receptor for the cytokine 
known as stem-cell factor (SCF); the intracytoplasmic portion of KIT 
functions as a tyrosine kinase. At present, GISTs are defined as spindle-
cell, epithelioid, or occasionally pleiomorphic mesenchymal tumours of 
the gastrointestinal tract that express the KIT protein.2,3 The KIT 
protein is often detected clinically by immunohistochemical assays for 
CD117 antigen. The definition of KIT-negative GISTs remains a focus 
of research, but for clinical purposes the important point is that the vast 
majority of GISTs express KIT. 
 
 
 xi
CLINICAL FEATURES 
 
 Most studies of the clinicopathological entity referred to as GIST 
before the year 2000, are likely to include a group of patients with true 
GISTs as well as other histological subtypes of spindle-cell sarcoma 
such as leiomyosarcoma. GISTs occur in both sexes at a similar 
frequency, but some data show male predominance.2,6 The median age 
at diagnosis is about 60. GISTs are occasionally found in young adults, 
but they are very rare in children.2 Nearly all GISTs arise as a result of a 
somatic mutation, but rare familial cases associated with mutated KIT 
have been identified. 
 
 The hereditary forms are characterised by the presence of multiple 
tumours and in some cases hyperpigmentation of the skin and the 
mucous membranes, systemic mast-cell disease, multiple naevi, urticaria 
pigmentosa, and diffuse spindle-cell hyperplasia in the myenteric plexus 
layer of the gastrointestinal tract.7–9 GISTs may also be a feature of the 
Carney triad, a very rare syndrome of unknown cause affecting mainly 
young women. 
 
 xii
 The triad includes gastric stromal sarcoma (generally epithelioid 
type), extra-adrenal paraganglioma, and pulmonary chondroma. Familial 
occurrence has been suggested for the Carney triad, but no detailed 
molecular genetic mechanism is known.10 A pathogenetic relation has 
also been suggested between neurofibromatosis type 1 (von 
Recklinhausen’s disease) and GISTs because of the high frequency of 
nonrandom association of these diseases.11 However, the vast majority 
of GISTs are sporadic, and predisposing factors are unknown. 
 
 GISTs are most commonly found in the stomach (40–70%), but 
they can occur in all other parts of the gastrointestinal tract. About 20–
40% of GISTs arise from the small intestine, and 5–15% from the colon 
and rectum.1,2,12,13 GISTs can also be found in the oesophagus (<5%), 
omentum (<5%), mesentery, or retroperitoneum.2,3,12 They typically 
grow in an endophytic way parallel to the bowel lumen, commonly with 
overlying mucosal necrosis and ulceration, and they vary in size from a 
few millimetres to 40 cm in diameter.12 Larger, high-grade GIST 
lesions, can be necrotic and haemorrhagic and show more mucosal 
ulceration than smaller GISTs, which might have been diagnosed in the 
past as purely benign lesions. Many GISTs are well confined by a very 
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thin surrounding pseudocapsule.14 Over 95% of patients present with a 
solitary primary tumour; in 10–40% of cases these tumours directly 
invade the surrounding organs.15,16 
 
 Many small GISTs are discovered incidentally during endoscopy 
or laparotomy done for other reasons such as submucosal or subserosal 
nodules, or during imaging examinations. At presentation, the most 
common symptoms of GISTs are vague abdominal discomfort or pain, 
presence of a palpable abdominal mass, feeling of abdominal fullness, 
and secondary symptoms resulting from tumour bleedingand associated 
anaemia. GISTs can also cause altered bowel function, bowel obstruction 
or perforation, dysphagia, and fever. Duodenal GISTs occasionally cause 
obstructive jaundice. GISTs are commonly discovered during emergency 
surgery for unexpected perforation of the gastrointestinal tract and 
consequent intra-abdominal blood loss.17 15–50% of GISTs present 
with overtly metastatic disease.1, 16, 18. 
 
 A peculiar feature of GISTs is that the great majority of 
recurrences are solely intra-abdominal. Macroscopic extraabdominal 
metastases are uncommon even in advanced disease, and they rarely 
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occur in the absence of intraabdominal recurrence. This feature contrasts 
with true leiomyosarcomas of the abdomen and gastrointestinal tract, 
which commonly give rise to pulmonary metastases.6,19 40–80% of 
GISTs recur despite histopathologically complete tumour resection. The 
most common sites of metastases are the peritoneum and the liver,1,6 
whereas regional lymph-node metastases are extremely rare.1,20 In one 
review of 60 patients with recurrent GIST, local recurrence occurred in 
76% of patients, half of whom had synchronous liver metastases, 15% 
liver metastases, and 7% peritoneal metastases.21 None had extra-
abdominal metastases at first recurrence. 
 
 Peritoneal metastases are most probably a result of tumourcell 
seeding from the primary tumour directly into the peritoneal cavity. 
Similarly, liver metastases most probably result from haematogenous 
seeding into the portal vein. 
 
Histopathology and immunohistochemistry 
 
 On histolgical analysis most GISTs look fairly benign, which is 
surprising in view of the malignant potential of the disease. However, the 
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histological appearance of GISTs can vary greatly among patients, and 
their malignant potential ranges from clinically benign tumours to 
aggressive cancers. The spindle-cell variant of malignant GIST (70%) 
corresponds to tumours previously classified as leiomyosarcoma, and 
many of the epithelioid or round-cell variants (30%) were previously 
thought to be leiomyoblastoma. Most tumours previously diagnosed as 
gastrointestinal autonomic nerve tumours (GANTs) are in fact 
GISTs.2,3,22 GANTs have been described as cells with axon-like 
cytoplasmic processes and synapse-like structures (seen on electron 
microscopy), with dense core granules and intercellular fibrils. 
 
 Tumours previously diagnosed as GANTs have subsequently been 
found to express KIT and to harbour essentially identical KIT mutations 
to GISTs.23 Also, electron microscopy shows that a substantial 
proportion of GISTs have similar ultrastructural features to GANTs. 
Thus, GANT should be regarded as a type of GIST and no longer be 
classed as a separate entity.3It is important to differentiate between 
GISTs, which constitute about 80% of gastrointestinal mesenchymal 
tumours, and the less common gastrointestinal nonepithelial neoplasms, 
leiomyoma, leiomyosarcoma (10–15% of mesenchymal tumours), 
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schwannomas (5%), and other malignant disorders such as melanomas, 
so that appropriate clinical decisions can be made (table 1). GISTs 
characteristically stain strongly for the CD117 antigen, an epitope of the 
KIT-receptor tyrosine kinase. Smooth-muscle neoplasms (leiomyoma 
and leiomyosarcoma), neurogenic tumours (schwannomas), and desmoid 
fibromatoses typically do not show this positive expression of 
CD117.2,3,22 
 
 Thus, CD117 immunostaining is an important method for 
diagnostic distinction. Typically, in GISTs, KIT is widespread 
throughout the entire tumour and is highlighted by cytoplasmic staining, 
sometimes showing a dot-like ‘golgi’ pattern.3 60%–70% of GISTs stain 
for CD34, a sialylated transmembrane glycoprotein also found in 
haemopoietic progenitor cells and endothelial cells.3,5,22,24 Up to 40% 
of GISTs are also positive for smooth muscle actin (SMA). 
 
 They rarely express desmin, an intermediate filament protein 
typical of muscle, or S100, a neural (schwann) cell marker, and they are 
negative for neurofilaments and glial fibrillary acidic protein.2 By 
contrast, leiomyosarcomas are positive for SMA and desmin but 
negative for KIT, and schwannomas are positive for S100 but negative 
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for CD117.3,22 Overall, strong KIT expression in the absence of 
smooth-muscle differentiation-related proteins is characteristic for 
GISTs, and these features aid the differential diagnosis between GISTs 
and most other types of gastrointestinal mesenchymal tumours. 
 
 KIT expression is not limited to GISTs, but some other neoplasms 
may stain positively for KIT in immunohistochemical assays. These 
tumours include a subset of soft-tissue sarcomas such as Ewing’s 
sarcoma and angiosarcoma, as well as other neoplasms such as 
melanoma, small-cell lung cancer, adenoid cystic carcinoma, ovarian 
carcinoma, sinonasal natural-killer/T-cell lymphoma, anaplastic large-
cell lymphoma, acute myelogenous leukaemia, seminoma, 
neuroblastoma, and mastocytomas. 
 
 However, these tumours are rarely included in the differential 
diagnosis of GISTs.2,25,26 Immunopositivity for KIT does not 
necessarily indicate KIT activation or the presence of a KIT mutation, 
and there is, as yet, little reason to believe that these other tumours 
would show a response to imatinib mesylate. 
 
 xviii
 
 
Cell of origin 
 
 Kindblom and colleagues suggested in 1998 that GISTs originate 
from stem cells that differentiate towards the interstitial cells of Cajal 
(ICCs), and that GISTs should be called gastrointestinal pacemaker-cell 
tumours.24 ICCs arisefrom precursor mesenchymal cells and are the 
pacemaker cells that bring about autonomous movement of the 
gastrointestinal tract.27 They intercalate between nerve fibres and 
muscle cells and can be seen in the adult intestine in and around the 
myenteric plexus.2 Both ICCs and GISTs express KIT protein, have 
similar ultrastructural features, and express the embryonic form of the 
heavy chain of smoothmuscle myosin;24,28 all these features support a 
common histogenesis. 
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 The precursor-cell hypothesis could also explain why KIT-
expressing mesenchymal tumours, with similar histology to GISTs, can 
arise outside the gastrointestinal tract in the omentum, mesentery, and 
retroperitoneum.29,30 ICC-like cells have also been identified in the 
omentum.31 The precursor-cell hypothesis could also account for the 
coexpression of KIT, SMA, and even desmin in some GISTs. In studies 
of immunohistochemistry and confocal microscopy of normal intestinal 
muscle, CD34 immunopositivity has been found in fibroblast-like cells 
located near the ICCs. Conversely, ICCs did not stain for CD34 in these 
studies, and no cells with concomitant CD34 and KIT positivity were 
found. These findings also support the hypothesis that GISTs originate 
from a more primitive precursor cell.32 
 
Diagnosis 
 
 The clinical prediagnostic investigation of GISTs is similar to that 
of other gastrointestinal malignant disorders. A doublecontrast series of 
radiographs may show a characteristic smooth-lined filling defect with 
clearly demarcated borders. On endoscopic examination, there may be a 
smooth protrusion of the bowel wall, lined with mucosa, which can also 
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show signs of bleeding and ulceration.14 Endoscopic ultrasonography 
may show a hypoechoic mass that is contiguous with the muscularis 
propria of the normal gut wall. In one ultrasonography study, presence of 
malignant GIST was suggested by the presence of a large (>4 cm) 
tumour with irregular extraluminal border, echogenic foci, and cystic 
spaces.33 Computed tomography (CT) and magnetic resonance imaging 
(MRI) are essential in assessment of primary tumour extension and the 
presence of metastases. 
 
 Most GISTs are submucosal and grow endophytically, which 
decreases the likelihood that a tissue diagnosis can be obtained 
preoperatively. Only about 50% of patients assessed by endoscopy are 
given a histological diagnosis preoperatively. Percutaneous fine-needle 
aspiration has been suggested as an initial diagnostic technique, if 
feasible, but it is not universally recommended because intra-abdominal 
tumour spillage is possible.14,34 Most oesophageal stromal tumours are 
benign,22 and endoscopic biopsy, for cases in which the mucosa 
surrounding the tumour is intact, is controversial because of the potential 
high risk of intraoperative oesophageal perforation.14,35 
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 During laparotomy, all resected margins should be carefully 
oriented and examined, and biopsy samples from grossly different areas 
of the excised tumour should be evaluated pathologically. Solid and firm 
areas should be included, as well as necrotic and haemorrhagic parts of 
the tumour. A minimum of one tissue section per centimetre of tumour 
diameter has been recommended for microscopic assessment of fixed 
tissue.14 KIT immunostaining should be done with appropriate positive 
and negative control samples to avoid falsely positive and negative 
results. Mast cells and ICCs stain strongly positively for KIT and may be 
used as positive internal controls. 
 
 Immunohistochemical staining for KIT (CD117), CD34, desmin, 
SMA, and S100 should be carried out. Mutation analysis of KIT is not 
considered mandatory in routine diagnostics, but this technique is 
currently being evaluated to see whether it might provide predictive 
information about the likelihood of a response to imatinib mesylate 
therapy. Additionally, a KIT mutation gives further support to the 
diagnosis of GIST. 
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Prognostic features 
 
 Assessment of the malignant potential of a primary GIST lesion is 
difficult in many cases, and even small GISTs (less than 2 cm in 
diameter) have uncertain malignant potential.3 The criteria used to 
predict biological behaviour also vary significantly with tumour location, 
for example, smoothmuscle tumours arising from the small bowel, colon, 
rectum, omentum, or mesentery are generally associated with a less 
favourable outcome than those arising in the stomach.12 Most 
oesophageal and colonic GISTs are malignant, whereas in the case of 
gastric GISTs, more indolent tumours seem to outnumber overtly 
malignant ones. However, with long follow-up their outcome may not 
differ greatly. Almost all incidental small (<1 cm) GISTs are clinically 
benign, whereas tumours larger than about 5 cm in diameter are 
generally malignant. Nonetheless, no cut-off diameter predicts 
subsequent malignant behaviour with certainty, and the optimum cut-off 
size may vary for different sites.12,13,15,36 
 
 The mitotic rate is one of the more reliable single factors in 
differentiating between GISTs of varying malignant potential. In general, 
 xxiii
most tumours with 0–1 mitoses per 10–50 high-power fields (HPFs) will 
not give rise to metastases, those with over five mitoses per 50 HPF are 
considered as malignant, and tumours with over 20–50 mitoses per 50 
HPF are classed as high-grade malignant.2,13–15. 
 
 However, a low mitotic count does not rule out malignancywith 
certainty, and vice versa, and the mitotic count is of limited value 
especially in assessment of the malignant potential of small-bowel 
GISTs.12 Other factors suggested to be associated with an adverse 
outcome include: incomplete surgical resection and tumour rupture at 
surgery;6 infiltration of tumour to the neighbouring structures; location 
of the primary tumour in the intestine;22 presence of coagulative tumour 
necrosis, high cellularity, and pronounced pleiomorphism; a high S-
phase fraction and DNA aneuploidy in flow cytometry or image 
cytometry; a high Ki-67 score; proliferating-cell nuclear-antigen 
expression; and presence of telomerase activity. In some studies the 
presence of KIT mutation has also been implicated.12,18. However, 
many of these features are predictive of outcome only in statistical 
analysis of large series of cases, and their usefulness on an individual-
case basis is limited. 
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 Altogether, there are many borderline malignant tumours within 
the spectrum of GISTs, ranging from indolent tumours to clearly 
malignant cancers. All GISTs should be considered as having some low 
malignant potential, and they should be described in terms of risk 
assessment, rather than using distinct benign and malignant categories.3 
The only certain indication of malignancy is tumour spread beyond the 
organ of origin at the time of diagnosis.13 However, most primary 
GISTs larger than 5 cm in diameter and with a mitotic count higher than 
five per 50 HPF are likely to behave in a malignant way. Similarly, 
GISTs larger than 10 cm in diameter have a high risk of aggressive 
behaviour whatever the mitotic count, and GISTs of any size with a high 
mitotic count (more than ten per 50 HPF) are also deemed to be high-risk 
tumours.3 
 
Outcome 
 
 Before about the year 2000, studies of GISTs included tumours 
that would not presently be classified as GISTs, and data are therefore 
contaminated by these cases. However, since GISTs constitute the 
majority of gastrointestinal sarcomas, the survival data from these 
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studies probably largely reflect the experience of patients with true 
GISTs. Most recurrences take place within 5 years of the primary 
diagnosis,12 but in the slowly proliferating subset of GISTs, metastases 
can appear more than 10 years after the primary diagnosis. 
 
 Outcome depends on the histopathological and clinical features. 
The reported overall or disease-specific 5-year survival is 28–60% 
among patients with malignant GIST; the median disease-specific 
survival is about 5 years for primary disease, and 10–20 months in 
recurrent or metastatic disease.1,6,16,18. According to one study, 
patients who have been diagnosed with GISTs with one to five mitoses 
per 50 HPF have median survival of 98 months, whereas those with 
GISTs with more than ten mitoses per ten HPFs have median survival of 
25 months.42 In another study, patients who had undergone curative 
surgery had 8-year disease-free survival of 80% when fewer than ten 
mitoses were present per 50 HPF compared with an 18- month median 
survival in patients with more high-grade lesions. 
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Molecular biology 
 
 The fundamental pathogenetic feature of the most common 
malignant phenotype of GIST seems to be activation of the KIT 
signalling pathway. KIT is a transmembrane tyrosine kinase encoded by 
the KIT proto-oncogene located on chromosome 4q11-q12.45 It is the 
cellular homologue of the oncogene v-kit of the Hardy-Zuckerman feline 
sarcoma virus. The natural ligand of KIT is SCF (also known as the 
mast-cell growth factor, Steel factor, or the KIT ligand). Unbound KIT 
protein is an enzymatically inactive monomer spanning the plasma 
membrane. Soluble SCF is predominantly a bivalent dimer, which causes 
homodimerisation of KIT by binding to the extracellular domain. This 
action results in activation of KIT via autophosphorylation of 
intracellular tyrosine residues.15. 
 
 Autophosphorylation creates docking sites for signal transduction 
molecules. Activated KIT then functions as a tyrosine kinase, 
transferring phosphate groups from ATP to the tyrosine residues of 
target proteins, which become activated in turn. The activation signalling 
cascade to the nucleus involves several proteins including MAP kinase, 
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PI3 kinases, STAT5, RAS, and JAK2,15,48-51 which have been 
implicated in KIT-induced mitogenesis and differentiation. 
 
 Structurally, KIT tyrosine kinase is a type III tyrosine kinase 
receptor, similar to receptors of macrophage colonystimulating factor, 
platelet-derived growth factor, and the haemopoietic growth factor FLT3 
ligand, each possessing five immunoglobulin-like extracellular repeats 
and a tyrosine kinase domain split into two by an insert sequence of 
variable length (figure 2). In addition to ICCs, KIT is normally expressed 
in mast cells, melanocytes, Leydig cells, spermatogonia, spermatids, 
haemopoietic stem cells, cutaneous basal cells, and breast epithelial 
cells,25,52 and it has important roles in haemopoiesis, melanogenesis, 
gametogenesis, and the development of mast cells and ICCs.27. 
 
 Almost all GISTs have constitutive activation (phosphorylation) 
of the KIT protein, and most have inframe mutations that preserve the 
expression of KIT. Stable transfection of mutated KIT cDNAs into 
murine lymphoid cells causes malignant transformation.5. Unlike the 
normal KIT protein, mutated KIT may not require SCF for dimerisation 
or autophosphorylation. This ligandindependent activation causes a shift 
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in the balance between cell survival and proliferation away from 
apoptosis. The frequency of KIT mutations in GISTs varies in different 
studies, according to the tumour type, and probably because of 
differences in the methods used to analyse the tumours. Up to 80–90% of 
metastatic GISTs have been reported to have mutated KIT,  and in some 
studies KIT mutations have been found in benign, borderline, and 
malignant GISTs at about equal frequency. Corless and co-workers 
found identical KIT mutations to those previously found in larger GISTs, 
in 11 (85%) of 13 of morphologically benign GISTs that were found 
incidentally at autopsy, endoscopy, or laparotomy, by use of a sensitive 
mutation-detection method (denaturing high-performance liquid 
chromatography). These small GISTs were all immunohistochemically 
positive for KIT, and ranged in size from 4 mm to 10 mm. If confirmed, 
these findings suggest that KIT mutations are acquired very early in the 
development of most GISTs and that KIT mutations alone may be of 
limited prognostic importance. KIT mutations have not been found in 
leiomyomas and leiomyosarcomas. 
 
 Family members with germline mutations of KIT have indolent 
and malignant GISTs from a young age and have the same mutation in 
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the germline, indolent GISTs, and malignant GISTs, which also suggests 
that KIT mutation is an early oncogenic event.15 KIT has 21 exons, and 
in sporadic GISTs the KIT mutations have been found in exon 11, 
encoding an intracellular juxtamembrane region of the receptor, in 50–
77% of cases. Exon-9 mutations, encoding a region located in the 
extracellular domain, are found in 3–18% of GISTs, and a few GISTs 
have mutations in exons 13 and 17, encoding the intracellular part of the 
receptor. Mutation of NF2 gene has also been described in GISTs. This 
finding is consistent with high incidence of GISTs in patients with 
neurofibromatosis. Loss of chromosome 1p or complete or partial loss of 
chromosomes 14 and 22 occurs in 50% or more of GISTs and may be 
involved in GIST pathogenesis and progression. However, such changes 
may be secondary, and activating mutations of KIT seem to have a 
central role in GIST pathogenesis.44 This idea is supported by a recent 
study that used 13, 826-element, cDNA microarrays to analyse gene-
expression patterns of KIT-mutation-positive GISTs. 
 
 In this study the expression profiles of GISTs were remarkably 
uniform with the KIT gene ranking the highest on the discriminator list 
and being highly expressed in every tumour studied. Therefore, mutated 
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KIT is an excellent molecular target for therapeutic interventions with 
KIT-selective tyrosine-kinase inhibitors. 
 
 
Surgery 
 
 Surgery remains the standard initial treatment for nonmetastatic 
GISTs. Careful pathological assessment should be done to differentiate 
GISTs from carcinomas and lymphomas. As with other soft-tissue 
sarcomas, a true capsule does not exist, and the tumour should be 
removed en-bloc with its pseudocapsule and, if possible, an adjacent 
margin of normal soft tissue or bowel. In cases where contiguous organs 
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are involved, en-bloc resection has been recommended wherever 
feasible.14 Since this process may require total gastrectomy in the case 
of gastric GISTs, pancreaticoduodenectomy for a duodenal GIST, or an 
abdominoperineal resection for tumours involving the rectum, associated 
morbidity can be substantial. In such cases, preoperative, neoadjuvant 
treatment with imatinib mesylate may eventually be considered, but at 
present no data are available to support this practice. A trial evaluating 
this treatment option is in progress in the USA. 
 
 In several studies, patients who had complete tumour resection 
had better overall survival than those who had less radical surgery.16. 
Although this difference may partly reflect aggressive biological features 
of GISTs that cannot be totally removed, an effort should be made to 
obtain histologically tumour-free tissue margins. The optimum width of 
the tumour-free margin has not been defined. Tumour rupture, 
spontaneously or during surgery, may be associated with an increased 
risk of development of peritoneal implants and should be avoided. 
Regional lymph-node resection is of unproven value, and extensive 
lymphadenectomy is not recommended.14. 
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 There are few data about the usefulness of resection of recurrent 
disease or intra-abdominal metastases. In some studies, tumour-specific 
mortality and overall survival have not differed significantly between 
patients who underwent complete resection of recurrent disease and 
those who had partial resection or biopsy alone.21 However, there is 
evidence that metastasectomy may improve survival in selected patients. 
Patients with well or moderately differentiated GIST, a disease-free 
interval between the diagnosis and detection of metastases of longer than 
12 months, and isolated resectable liver metastases are more likely to 
benefit from metastasectomy than patients who have rapidly progressing 
or widespread GIST. Many patients who have a bleeding tumour or 
tumour-related bowel or biliary-tract obstruction achieve efficient 
palliation with surgery. 
 
 However, since imatinib mesylate was developed as a therapeutic 
alternative, surgery for metastatic GIST has largely been replaced by 
drug therapy, and primary surgery for metastatic GIST should probably 
be attempted only in patients who have bleeding or obstructive disease. 
The question of whether surgical resection should be done to remove 
residual masses, after imatinib mesylate therapy, is unanswered and 
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requires further research. We suspect that this approach would be a very 
reasonable option for patients with low-volume metastatic disease. 
 
Radiotherapy 
 
 The impact of radiotherapy on outcome is unknown. Many 
visceral sarcomas are not readily amenable to radiotherapy because of 
organ motility, and postoperatively contaminated bowel loops may 
relocate to remote sites. The large target volumes needed and the limited 
radiation tolerance of the intra-abdominal organs limit the usefulness of 
radiotherapy. Fixed lesions on the abdominal wall or adjacent organs 
have been treated with postoperative radiotherapy, but recurrences both 
within and outside the radiation field have been frequent.16 At present, 
radiotherapy is not a standard postoperative therapy for GIST, and in 
most cases should be reserved for limited palliative settings or for 
research of new strategies. 
 
Chemotherapy 
 
 Attempts to treat malignant GISTs with systemic chemotherapy 
have been almost universally unsuccessful. In one study, only 3 of 43 
 xxxiv
(7%) patients with gastrointestinal soft-tissue sarcomas (most tumours 
probably GISTs) responded to a combination of doxorubicin and 
dacarbazine, whereas 22% of patients with uterine leiomyosarcomas and 
21% of patients with leiomyosarcomas of other sites responded to this 
combination (p=0·05), suggesting relative chemoresistance of 
gastrointestinal soft-tissue sarcomas. Similar results have been obtained 
in other studies. Only 1 of 21 (5%) patients with GISTs treated with 
combination chemotherapy consisting of dacarbazine, mitomycin c, 
doxorubicin, cisplatinum, and sargramostine showed a response, and no 
gastrointestinal soft-tissue sarcomas responded to a combination of 
etoposide and ifosfamide. 
 
 The unresponsiveness of GISTs to drugs commonly used in the 
treatment of soft-tissue sarcomas may be explained partly by the 
frequent expression of P-glycoprotein and multidrug resistance protein 1 
(MDR1) in GISTs. study, 38·4% of GISTs expressed P-glycoprotein and 
35·4% expressed MDR1 protein, whereas only 13·4% and 13·3% of 
gastrointestinal leiomyosarcomas, respectively, stained positively for 
these proteins.19In onestudy, 38·4% of GISTs expressed P-glycoprotein 
and 35·4% expressed MDR1 protein, whereas only 13·4% and 13·3% of 
 xxxv
gastrointestinal leiomyosarcomas, respectively, stained positively for 
these proteins.19 
 
Imatinib mesylate 
 
 Imatinib mesylate is a competitive inhibitor of certain tyrosine 
kinases including the intracellular kinases ABL and BCR-ABL fusion 
protein present in some leukaemias, KIT, and the platelet-derived growth 
factor receptors. Imatinib mesylate inhibits these tyrosine kinases at 
submicromolar concentrations, but has little or no effect on many other 
tyrosine or serine/threonine kinases. It is a small multiringed molecule, 
which competes with ATP for its kinase-binding site, and prevents the 
kinase from transferring phosphate from ATP to tyrosine residues of the 
substrates. This action inhibits downstream signalling from the kinase, 
which switches the balance towards apoptosis. Imatinib mesylate is very 
well absorbed after oral administration and is available as capsule 
formulations. It is metabolised mainly in the liver by the P450 
isoenzyme CYP3A4, and the metabolites are mostly excreted via the bile 
into the stools. The half-life in the circulation is about 20 h, which is 
compatible with oncedaily administration. Preclinical studies suggest 
that maintenance of imatinib mesylate serum concentrations above 1 
 xxxvi
_mol/L are needed for optimum therapeutic effects, and such 
concentrations are obtained in most patients with daily doses of 300 mg 
or greater. 
 
Effectiveness of imatinib mesylate in advanced GIST 
 
 Based on two studies, imatinib mesylate is the first effective drug 
in the treatment of metastatic GIST. The US–Finland study reported a 
response rate of 54% among 147 patients with inoperable or metastatic 
GIST treated with a daily dose of 400 mg or 600 mg with follow-up of at 
least 6 months. In addition, 28% had minor response or stable disease, 
and only 14% showed primary resistance to the drug. Similar results 
were reported from a trial by the European Organization for Research 
and Treatment of Cancer, in which 36 patients with advanced GISTs 
were treated with a daily dose of 400–1000 mg. 53% had confirmed 
partial responses and 17% had as yet unconfirmed partial responses or 
more than20% regression, and only 11% of patients had progression. In 
these studies, about 90% of patients with symptoms had marked relief of 
them. In both studies, inclusion required histology compatible with GIST 
and KIT expression verified by immunohistochemistry. 
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 Response to imatinib mesylate can occur rapidly, even in patients 
with a large tumour burden but regression can also be slow, particularly 
after an initial rapid phase of tumour regression. The median time to 
response is about 13 weeks. Interestingly, tumour lysis syndrome has not 
been described in these patients, even though hydration or allopurinol 
have not been routinely administered alongside imatinib mesylate. Liver 
lesions commonly acquire a cyst-like appearance after the start of 
treatment, and may thus seem better delineated on magnetic resonance 
(MR) or computed tomography (CT) images they should not be confused 
with new lesions or progressive disease. Histologically, the cyst-like 
lesions consist of hyaline degeneration, but a few remaining KIT-
positive cells could represent dormant or slowly proliferating GIST cells 
and may persist for several months in these lesions. The malignant 
potential of the few persistent intralesional KIT-positive cells is not 
currently known. 
 
 In addition to CT and MRI, fluorodeoxyglucose (labeled with 
fluorine-18) positron emission tomography (FDG-PET) may be a useful 
imaging technique to assess response to imatinib mesylate. Glucose 
uptake of GIST lesions decreases within a few hours to a few days after 
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the start of imatinib mesylate treatment, which can be verified by FDG-
PET. The technique could be helpful in problematic cases to make a 
distinction between intratumoral bleeding and disease progression. The 
PET scan responses can also predict subsequent tumour volume 
reductions found on CT or MRI. In one study, patients with an exon-11 
KIT mutation had a significantly higher rate of response to imatinib 
mesylate therapy (72%) than patients whose tumour had an exon-9 
mutation (32%) or no detectable mutation (12%), and the time to 
treatment failure was also longer in patients with an exon-11 mutation. 
 
 The optimum dose of imatinib mesylate in the treatment of GISTs 
is not yet known and is being studied in current randomised phase III 
trials. Toxicity increases with increasing dose, and in one study, 800 mg 
was the maximum tolerated dose when taken for 8 weeks. No statistical 
difference in the response rate was found in another study of 400 mg and 
600 mg daily doses, although these data are underpowered and the 
results of ongoing large-scale studies are needed before conclusions are 
reached. 
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 Data from studies on chronic myeloid leukaemia suggest that 
doses less than 300 mg may be too small for the competitive inhibition 
of the BCR-ABL kinase and should be avoided in clinical practice. 
Overall, present data suggest that a daily dose of400 mg or higher should 
be used in the treatment of patients with metastatic or unresectable 
GIST. 
 
 The optimum treatment duration remains unknown, but in 
metastatic disease administration of imatinib mesylate for several 
months to a few years is likely to be needed. In the US–Finland study, 
objective major responses were durable and generally continuing at 
follow-up of at least 9 months, with no median duration of responses yet 
evident. So far, responses lasting up to 24 months have been observed  
but secondary resistance to imatinib mesylate has been seen in some 
patients who initially responded to the drug. The proportion of patients 
who will relapse after a response is not currently known. 
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Tolerability and safety of imatinib mesylate 
 
 Tolerability has been acceptable with daily doses of 800 mg or 
less. The most common adverse effects include periorbital and leg 
oedema  transient nausea associated with drug ingestion, muscle cramps, 
diarrhoea, headache, dermatitis, fatigue, anaemia, and neutropenia. Most 
of these side-effects are mild to moderate in severity, and grade 3–4 
toxic effects occur in less than 30% of patients at a dose of 400–600 mg 
per day.A few patients (5%) have had a tumour-associated bleeding 
either into the abdominal cavity or into the bowel, and patients who 
develop symptoms that suggest acute bleeding may need emergency 
care. 
 
 Most adverse effects resolve within a few days to weeks after 
cessation of treatment, and most patients can continue at a lower dose. 
Imatinib-mesylate-associated oedema can be treated with diuretics. 
Drug-ingestion-related nausea rarely requires antinausea medication, 
although some patients are given a divided dose. 
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 The muscle cramps typically occur in the fingers and legs, and are 
transient, most requiring no specific therapy. Interactions with other 
drugs metabolized by CYP3A4 are possible. In particular, concomitant 
use of paracetamol or warfarin is not recommended 
 
Future directions and unresolved questions 
 
 Imatinib mesylate is a major breakthrough in the treatment of 
advanced GISTs and is the first effective systemic therapy for this 
disease. However, several important questions remain unanswered: the 
required duration of imatinib mesylate therapy; the proportion (if any) of 
the patients with metastatic disease who will achieve long-term disease 
control, and whether treatment results can be improved with combination 
therapies. 
 
 In the treatment of BCR-ABLexpressing leukaemia, resistance to 
imatinib mesylate is commonly associated with reactivation of BCR-
ABL signalling due either to a secondary mutation resulting in 
substitution of threonine with isoleucine at a critical binding site of the 
drug or to progressive BCR-ABL gene amplification.80 Little is known 
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about the resistance mechanisms of imatinib mesylate in the treatment of 
GISTs, but these are currently being studied. 
 
 An important strategy, which is likely to affect cure rates, is 
whether adjuvant therapy will benefit patients after macroscopically 
complete removal of malignant GIST, or after excision of GIST with 
intra-abdominal metastases amenable to surgical removal. Many such 
patients will develop inoperable systemic metastases within a few years 
of primary surgery, and adjuvant therapy with imatinib mesylate for 
subclinical metastatic disease might lead to a better cure rate than 
treatment for overtly metastatic disease. In the absence of data from 
clinical trials, there is no objective basis for recommending adjuvant use 
of imatinib mesylate, but the potency of the drug in metastatic disease 
certainly justifies the rapid application and study in the adjuvant setting. 
Similarly, the role of neoadjuvant imatinib mesylate needs to be studied 
especially in cases where extensive surgery resulting in loss of organ 
function is the only other option. Combination therapies with 
conventional chemotherapeutic drugs and other signal transduction 
inhibitors also need to be investigated. 
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 The molecular targeting of the critical pathogenetic mechanism 
underlying GIST has given patients new hope, and has provided 
physicians with a highly effective and well tolerated therapeutic option 
for a disease for which no systemic therapy existed previously. 
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RESULTS 
 
 
 
 
 Thirty one patients with GIST treated at our institute were 
included in the study. The median age was 55 years (14-70 years). From 
the 31 patients were 8 (25.8%) females and 23 (74.2%) males. Among 
these, 24 patients has first time surgery for a GIST at our institute and 7 
patients were presented with advanced metastatic disease which were 
deemed inoperable. All the 7 patients were started on Imatinib. 
 
 Out of the 24 operated patients, 2 patients presented with 
metastasis, primary alone was resected. Detailed tumour localizations are 
shown in Table 1. Applying the Fletcher classification, 4 patient had low 
risk, 4 had intermediate risk and 16 patient had high risk. This reflects 
that the majority of the patients had an intermediate or high risk of an 
aggressive behaviour of their GIST. Regarding tumour size 5/24 of all 
tumours were smaller and 19/24 larger than 5 cm. 
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Table 1 Tumour characteristics 
 Stomach Small intestine Rectum Total
Tumuor size      
< 5cm 2 2 1 5 
5-10cm 7 1 1 9 
10-15cm 2 - - 2 
15-20cm 3 3 1 7 
>20cm 1 - - 1 
Total (n) 15 6 3 24 
Mitosis      
<5/50 hpf 7 2 - 9 
>5/50 hpf 8 4 3 15 
Fletcher classification     
Very low risk - - - 0 
Low risk 2 2 - 4 
Intermediate 3 - 1 4 
High 10 4 2 16 
     
Necrosis + 12 2 1 15 
Type of resection     
Segmental /TG 10 4 - 14 
APR   2 2 
Multi organ 5 2 1 8 
Status      
Disease free 12 1 1 14 
Recurrent disease 3 
 
5 2 
 
10 
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Surgical procedures  
 
 The surgical procedures carried out in this study varied from 
wedge resection of the tumour to complex multivisceral surgery. 
Multiorgan resection were performed in 8/24 patients. All the surgical 
procedures are summarized in Table 2. Complete tumour resection (R0) 
was achieved in 22/40 patients, whereas 2/24 patients had incomplete 
tumour resection (R2). One patient who underwent APR had positive 
iliac nodes (2/5), which is a rare feature of GIST. 
 
Table 2 Surgical procedures 
 
Resection of stomach   
Wedge resection 13 
Total gastrectomy 2 
Small bowel resection  
Segmental resection 5 
Whipple procedure 1 
Rectal surgery  
Abdominoperineal resection 2 
APR+ prostatectomy 1 
Splenectomy  5 
Distal pancreatectomy  2 
Partial liver resection  1 
Partial cystectomy 1 
Tumour spill  4 
R0 resection  22 
R1 resection - 
R2 resection 2 
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Complications  
 
 Post-operative complications were observed in 3/24 patients. 
There was no post-operative mortality (until day 30). One patient had 
urinary fistula following APR and another patient had faecal fistula 
following multiorgan resection. Both these patient had incomplete 
tumour resection (R2). The third patient had persistent post-operative 
fever, managed appropriately. 
 
Survival and tumour recurrence  
 
 The median disease free survival time was 43.6 months with a 
median followup of 13 months (6- 88 months). At 5 years the probability 
of disease free survival was 45.8%. 10 out of 24 patients developed 
recurrence on follow up. In five patients liver alone was the site of 
metastasis. One patient developed metastases in liver and peritoneum. 
One developed recurrence in the small bowel, one on the dome of the 
urinary bladder and one patient developed pelvic recurrence. One patient 
developed lung metastasis. Among the 10 patients who developed 
recurrent disease three underwent secondary surgery, resulting in R0 
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resection. The secondary resections were, one liver metastasectomy, one 
segmental resection of jejunum and one partial cystectomy. Among the 
recurrences the primary sites of GIST were small intestine in 5 patients, 
stomach in 3 patients and rectum in 2 patients. All the 10 patients were 
started on Imatinib. Out of this 10 patients, one patient died after 4 
months of primary surgery. Remaining 9 patients are alive with disease 
till date. 
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 The probability of DFS at 5 years is 100% for tumours with 
mitotic count <5/50 hpf and 26.8% at 3 years for >5/50 hpf (p=0.006). 
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 l
 The probability of DFS at 5years for tumours without necrosis is 
80% and 26% at 3 years for tumours with necrosis (p=0.0046). 
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 Tumour size >5cm was also found to be a poor prognostic factor 
although it did not reach statistical significance. The probability of DFS 
at 5 years for tumours <5 cm is 80% and 36.8% at 5 years for tumours 
>5 cm (p=0.54). 
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 Positive margin is a strong prognostic factor for recurrence. Out of 
the 24 operated patients, 2 patients had positive margins and both of 
them recurred. The primary tumour site was also found to be a strong 
prognostic factor for recurrence. Out of the 6 patients with primary GIST 
of small intestine 5 recurred (one patient had R2 resection). Among the 6 
patients with rectal primary 2 have recurred (one had R2resection). Out 
of the 15 patients with primary GIST of stomach, only 3 have recurred. 
The extend of surgery and tumour spill were not found to be of any 
prognostic significance. Patient characteristics like age and sex showed 
no prognostic value for the development of a recurrent disease. 
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DISCUSSION 
 
 
 
 
 Most studies of the clinicopathological entity referred to as GIST 
before the year 2000, are likely to include a group of patients with true 
GISTs as well as other histological subtypes of spindle-cell sarcoma 
such as leiomyosarcoma.  
 
 Our study included patients on the basis of c-kit positivity.  
 
 GISTs occur in both sexes at a similar frequency, but some data 
show male predominance.2,6 The median age at diagnosis is about 60. 
 
 Our male: female ratio is 4:1, and the median age is 55 years. 
 
 GISTs are most commonly found in the stomach (40–70%), but 
they can occur in all other parts of the gastrointestinal tract. About 20–
40% of GISTs arise from the small intestine, and 5–15% from the colon 
and rectum.1,2,12,13 GISTs can also be found in the oesophagus (<5%), 
omentum (<5%), mesentery, or retroperitoneum.2,3,12. 
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 In our series also the commonest site is stomach, constituting 
62.5%. 40–80% of GISTs recur despite histopathologically complete 
tumour resection. The most common sites of metastases are the 
peritoneum and the liver,1,6 whereas regional lymph-node metastases 
are extremely rare.1,20. 
 
 In our study also 41.66% developed recurrence. Commonest site 
of recurrence is liver. One patient with GIST of rectum had lymph node 
metastasis. 
 
 Despite the great success of Imatinib in the treatment of metastatic 
GIST, primary surgery remains the cornerstone in the treatment of 
localized and resectable GIST. Recurrent disease is still a great problem. 
Therefore primary risk adapted surgery is the most important factor to 
avoid an early tumour recurrence and it is important to identify patients 
who may be candidates to receive an adjuvant treatment after complete 
tumour resection. 
 
 The criteria used to predict biological behaviour vary significantly 
with tumour location, for example, smooth muscle tumours arising from 
the small bowel, colon, rectum, omentum, or mesentery are generally 
associated with a less favourable outcome than those arising in the 
stomach.12 
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 Our series supports the theory that GIST arising in sites other than 
stomach has a more aggressive behaviour. In our series Out of the 6 
patients with primary GIST of small intestine 5 recurred (one patient had 
R2 resection). Among the 6 patients with rectal primary 2 have recurred 
(one had R2resection). Out of the 15 patients with primary GIST of 
stomach, only 3 have recurred. 
 
 As per our results primary GIST of small intestine is the most 
aggressive and GIST of stomach is the least aggressive, similar to results 
shown by most of the studies. 6,12. 
 
 The mitotic rate is one of the more reliable single factors in 
differentiating between GISTs of varying malignant potential. In general, 
most tumours with 0–1 mitoses per 10–50 high-power fields (HPFs) will 
not give rise to metastases, those with over five mitoses per 50 HPF are 
considered as malignant, and tumours with over 20–50 mitoses per 50 
HPF are classed as high-grade malignant.2,13–15. However, a low 
mitotic count does not rule out malignancy with certainty, and vice 
versa, and the mitotic count is of limited value especially in assessment 
of the malignant potential of small-bowel GISTs.12 
 
 lvi
 Our results showed strong correlation of mitotic count with 
tumour recurrence, which reached statistical significance. The 
probability of DFS at 5 years is 100% for tumours with mitotic count  
<5/50 hpf and 26.8% at 3 years for >5/50 hpf (p=0.006). 
 
 Other factors suggested to be associated with an adverse outcome 
include: incomplete surgical resection and tumour rupture at surgery;6 
infiltration of tumour to the neighbouring structures; multiorgan 
resection, location of the primary tumour in the intestine;22 presence of 
coagulative tumour necrosis, high cellularity, and pronounced 
pleiomorphism; a high S-phase fraction and DNA aneuploidy in flow 
cytometry or image cytometry; a high Ki-67 score; proliferating-cell 
nuclear-antigen expression; and presence of telomerase activity. 12,18. 
 
 In our series also incomplete resection is a strong predictive factor 
of recurrence. Out of the 24 operated patients, 2 patients had positive 
margins and both of them recurred. 
 
 Presence of necrosis in the tumour showed strong correlation with 
tumour recurrence, which reached statistical significance. The 
probability of DFS at 5years for tumours without necrosis is 80% and 
26% at 3 years for tumours with necrosis (p=0.0046).  
 lvii
 Tumour spill alone, with complete resection of the tumour did not 
show a prognostic value for recurrence in our study. Similarly extend of 
surgery did not influence DFS in our series. 
 
 Currently adjuvant therapy trials are being conducted to evaluate 
the benefit of Imatinib in those GIST patients who have a substantial risk 
of relapse after complete surgery. Furthermore the administration of 
Imatinib in patients with advanced GIST preoperatively to avoid 
multivisceral surgery is still an individual decision as data from a 
controlled trial are still missing. 
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CONCLUSION 
 
 
 
 
 Primary surgery remains the cornerstone in the treatment of 
localized and resectable GIST. Recurrent disease is still a great problem. 
Summarizing our results with the influence of high mitotic count, 
presence of tumour necrosis, large tumour size, incomplete surgical 
resection and primary site other than stomach on the DFS, which is 
reflected by a high rate of recurrences, we support the concept that all 
patients with these high risk features need to be assessed for adjuvant 
treatment with Imatinib. 
 
 Considering the 100% chance of recurrence with an incomplete 
resection, neoadjuvant treatment with Imatinib followed by surgical 
resection and continuing of Imatinib administration is a reasonable 
option. This combination strategy may provide survival benefit. But it 
remains to be determined whether this multimodal approach may exceed 
the benefits associated with Imatinib monotherapy. 
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